Prevention strategies of this condition are different from the one used for BRCA1/2 mutation carriers, since LFS component tumors also include soft tissue sarcomas, osteosarcoma, brain tumors, and adrenocortical carcinomas. This evidence concerns the gene BRCA1 and soft tissue sarcoma.